Immunodermatology News

Upadacitinib reduced all clinical disease measures including itch-related outcomes at 16 weeks in patients with moderate to severe atopic dermatitis, according to phase 2b study results published in Journal of Allergy and Clinical Immunology.

Preliminary findings from Emma Guttman-Yassky, MD, PhD, and colleagues demonstrate a novel use of dupilumab for managing chronic keloids with reductions in skin fibrosis and keloidal scarring, which may suggest a potential underlying Th2 pathogenesis in keloid formation.

Researchers suggested there is a dose relationship between smoking exposure and cutaneous manifestations in systemic lupus erythematosus, which highlights the importance of smoking cessation to improve outcomes, according to a presentation at the American College of Rheumatology/Association of Rheumatology Professionals annual meeting.

Be sure to check out Healio Dermatology’s live coverage from the American Society for Dermatologic Surgery annual meeting.

Among patients with vitiligo, treatment with ruxolitinib cream resulted in substantial improvements in total-body repigmentation at week 52 assessed by a 50% or more improvement from baseline in the total vitiligo area severity index, in a phase 2 study building upon previous data, according to data presented at European Academy of Dermatology and Venereology Congress.

Treatment with bimekizumab, an interleukin-17A and IL-17F inhibitor in adults with chronic plaque psoriasis, resulted in at least a 90% improvement in the Psoriasis Area and Severity Index and Investigator Global Assessment score of clear or almost clear, according to phase 3 results from the development program BE VIVID by UCB.

Bermekimab, which neutralizes interleukin-1 alpha, improved all disease measures of atopic dermatitis, including a large reduction in pruritus, according to phase 2 trial results presented at the European Academy of Dermatology and Venereology Congress by Alice Gottlieb, MD, PhD, of Icahn School of Medicine at Mount Sinai.

Patients with moderate to severe alopecia areata who were assigned to CTP-543, an oral Janus kinase inhibitor from Concert Pharmaceuticals, achieved a 50% relative reduction in Severity of Alopecia Tool score at 24 weeks, according to data presented at the European Academy of Dermatology and Venereology Congress.

The safety and efficacy of Ilumya were maintained after 4 years of treatment among patients with plaque psoriasis enrolled in the open-label reSURFACE1 trial, according to data presented at the European Academy of Dermatology and Venereology Congress.

SAN DIEGO — Early screening and early diagnosis are critical to managing systemic sclerosis, according to a presentation at the 2019 Congress of Clinical Rheumatology West.